Nalaganje...
Golimumab for the treatment of ulcerative colitis
Introduction: Tumor necrosis factor antagonists have revolutionized the therapeutic management of inflammatory bowel disease. Infliximab and adalimumab were the first biological agents used to induce and maintain remission in ulcerative colitis. More recently, a third tumor necrosis factor antagonis...
Shranjeno v:
| izdano v: | Expert Opin Biol Ther |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Taylor & Francis
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5490638/ https://ncbi.nlm.nih.gov/pubmed/28472597 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14712598.2017.1327576 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|